Prudential sets scrip reference price at $13.83 per share

Prudential set a scrip reference price of $13.834482 per new ordinary share for its scrip dividend alternative linked to the 2025 second interim dividend (dividend = $0.1889). Shareholders needed a minimum of 74 ordinary shares on the March 27 record date to participate (threshold = reference price / dividend, rounded up). The reference price is the five-day average middle-market LSE price starting on the ex-dividend date of March 26 and was converted to USD using Bloomberg WMR mid-point spot rates at ~11:00 a.m. London time.

Analysis

The scrip route is functionally a small but non-trivial equity issuance in disguise: if uptake is high, outstanding shares can increase in the low-single-digit percent range, creating immediate EPS dilution while preserving cash on the balance sheet for redeployment. That creates a two-part market impact — a near-term supply overhang around settlement and a medium-term optionality premium if management actually deploys the conserved cash into higher-return markets where the firm operates.

Microstructure and retail mechanics matter here. A rounding/lot-size threshold creates buy-to-qualify behavior from small holders that can provide short-lived support ahead of record/settlement dates, then flip to selling once new lines trade free, so expect intra-period volatility clustered around listing-specific times and across the three listings (LSE/HK/NYSE). FX and cross-listing conversion mechanics add a second-order arb window: small basis moves between listings are likely to exceed transaction costs for short windows and will be amplified by active corporate flows around the dividend election.

Key catalysts and risks are therefore timing- and behavior-driven: price action over the next 2–6 weeks will reflect take-up rate and retail activity, while 3–12 months of performance depends on whether preserved cash is deployed into accretive opportunities or used merely to offset future dividends. Tail risks include higher-than-expected take-up (larger dilution), adverse currency moves that shift the reference math, or a management pivot back to cash payouts/buybacks that reprice the optionality embedded in this operation.

Key Decisions for Investors

• Pair arbitrage (days–2 weeks): implement a market-neutral cross-listing pair — long the relatively cheaper listing and short the richer listing (PRU on LSE vs PUK ADR on NYSE / HK listing) sized to delta-neutral exposure. Target 0.5–1.5% gross capture; hard stop at 0.5% adverse basis move, scale out on 50% capture.
• Tactical long (3–6 months): modest long exposure to PUK (1–2% NAV) or buy a 6-month call spread to limit downside and retain upside if management redeploys cash into high-ROIC Asia markets. Risk: ~1–3% immediate dilution; Reward: >10% upside if reinvestment yields visible ROIC improvement; initial stop-loss at 6% drawdown in spot value.
• Post-settlement short/mean-reversion (2–6 weeks after settlement): short on settlement-related supply flip if price fails to absorb new shares — target 3–6% downside, tighten stop at 2% adverse move. Use low-cost borrow only and position size to limit mark-to-market; close if buyback or cash-return announcement emerges.
• Monitor catalysts (ongoing): set alerts for (1) announced use of preserved cash (M&A, capex), (2) cross-listing basis widening >1%, and (3) regulatory/ADR conversion statements. These events should trigger either scaling into longs (if accretive deployment) or exiting exposure (if dilution is coupled with weak reinvestment signals).